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In this video Q&A, we talk to Paul Wicks about the emergence of participant-led research, and discuss how this field
may be expected to develop in the near future, particularly with regard to personalized medicine.
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Paul Wicks is a keen advocate on the power of personalized
medicine in improving health outcomes. In his current role
as Vice President of Innovation at PatientsLikeMe, he is
responsible for the scientific and medical validity of the
research platform of PatientsLikeMe. As an neuropsych-
ologist, he leads a team of scientific researchers, who gen-
erate insights from the personal health data shared by
patient members. Prior to joining PatientsLikeMe, Dr
Wicks worked directly with patients from around the
world to study cognition in rare forms of motor neuron
disease (also known as amyotrophic lateral sclerosis
(ALS)) and the psychological consequences of Parkin-
son’s disease.
In this interview (Additional file 1), we talk to Dr
Wicks about the work produced by the PatientsLikeMe
R&D team under his direction, which includes numerous
peer-reviewed publications in major scientific journals.
We also discuss the possible future directions of this
evolving form of clinical research.
Edited transcript
1. Tell us a bit about yourself and how you became
involved in clinical research driven by online patient
communities
I’m a neuropsychologist by training, and I started out
my research career investigating cognitive aspects of
motor neuron disease – or ALS, as it’s known in the US.
At that time in the early 2000s, the Internet was grow-
ing, was becoming more widely used, and was no longer
just for hobbyists and academics. In 2002, I took overCorrespondence: pwicks@patientslikeme.com
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unless otherwise stated.the running of a website at Kings College Hospital,
called “BUILD” – Building User Involvement in Motor
Neuron Disease. That project had been set up by a nurse
as a research project, to try to gather more patient infor-
mation about how we could improve the services that
we were offering at the hospital. They tried a variety of
different ways of engaging with patients; there were real-
world support groups, there was a newsletter, there was
a phone line, and there was the online message board.
Actually, it was the online message board that proved
the most sustainable over time.
When the research funding came to an end, we were
looking for volunteers to keep it running to some extent.
There were two young-onset ALS patients, just in their
20s, talking to one another. I knew a little bit about the
web at the time, so I thought I’d take over and volunteer.
In my evenings, I would moderate this website and people
would ask questions like: “Why do we have to have placebo
in randomized control trials?” I was just a student, so I
didn’t know. So I would go and ask the head of clinical
trials, and she would tell me, and I would tell them. I
ended up becoming this sort of translation layer be-
tween medical science and patient understanding. That’s
something that I’ve continued with to this day.2. PatientsLikeMe is one of the first examples of a patient
network that has taken control of information exchange
about research into their diseases. Can you explain how
this works and how you got involved?
Back in 2005–2006, PatientsLikeMe was just being started
by a family affected by ALS. They were trying to come up
with ways to help their brother, Stephen Heywood, who
was diagnosed with the disease when he was 29. The ideais is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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base for symptom management (which at the time was
very thin), what if people shared their experiences to say,
“Well this dosage of amitriptyline worked really well for
excessive saliva, but it also caused constipation.”? If people
could share that sort of information systematically, then
perhaps we could do research with it; perhaps we could
do scientific analysis.
Some of the users of BUILD were the beta testers of
PatientsLikeMe, and it was through that initiative that I
came into contact with the Heywood family. I reached out
to them and said what an interesting idea I thought this
was, and they asked if I would moderate their forum. So I
took what I’d been doing in the UK and translated it over
to PatientsLikeMe.
ALS was the first condition discussed on PatientsLikeMe.
We give people the opportunity to measure their condition
by giving them patient-reported outcome measures and
let them track their treatments against that. They can
add information on prescription treatments, supple-
ments, over-the-counter treatments, exercises, as well as
the symptoms that they’re experiencing, either through
their disease, or they can add other diseases, other
symptoms. They can also add lab measures – things like
their forced vital capacity or blood tests etc.
The real difference between a system like PatientsLi-
keMe and a clinical registry is that all the members of
the system can see all of the data of everybody else. If
you think of a personal health record that was online, it
might be just between you and your doctor. Or if you
think of something like LinkedIn, you have to give per-
mission before two profiles can connect. It’s not like that
on PatientsLikeMe. On our system, everybody can see
everybody else’s data. So this is a very different approach
that is more about openness and sharing, rather than
privacy and protection.
What that allows is much more rapid research, much
more rapid discovery. We’re asking questions in a scien-
tifically rigorous way. We think about: what are the right
questions to ask? What are the meaningful questions
that patients can answer about their condition? What
are the things which they don’t have insight into? For
example, you don’t know your blood pressure right now,
but you know how tired you are. So, we have to focus
on what the right questions are that we can ask and
what’s really relevant for the condition.
3. How, in your opinion, are patients starting to influence
clinical research? Are there any examples?
There’s ‘patient-centered research’, which takes the existing
research infrastructure and brings patients in. So it says:
we’re going to do an observational study, we’re going to
do a clinical trial, we’re going to set up a patient advisory
board, etc. We’re going to ask selected members with thiscondition, or caregivers, to come and comment to give us
advice on different things; for example: what are the most
important research questions here, or do people really
understand this outcome measure, or how can we make
sure we communicate things clearly? I think that’s very
important, and I think that’s long overdue.
“Participant-led research” is slightly different. That’s say-
ing: no, we’re not going to use the existing infrastructure
of research, like hospitals and trained scientists, etc. We’re
going to take some of those skills and transfer them over
to the participants themselves. One example of that would
be the lithium study that was conducted in about 2008–
2009 by a group of people affected by ALS (Figure 1).
They were responding to a clinical trial which had been
published in the peer-reviewed literature (in PNAS
[Proceedings of the National Academy of Sciences]), by an
Italian group which claimed that lithium carbonate – a
drug frequently used for the treatment of bipolar dis-
order – would halt or significantly delay the progress
of this rapidly fatal, incurable disease. The title of the
paper even said, “Lithium delays amyotrophic lateral
sclerosis.” Members of our site translated the abstract
out of the original Italian, using Google Translate. They
were already trying to work out the best protocol for
getting hold of this drug, before the medical research
establishment had even read the published findings.
What ended up happening was, in the original Italian
study they had got 16 patients treated with lithium car-
bonate, and they compared those with 28 controls who
weren’t taking it. Within about six months, there were
160 patients who had got hold of lithium off-label – so
that’s 10 times the sample size in the published literature.
Led by a Brazilian patient, Humberto, and a caregiver in
the States, called Karen, they started crowd-sourcing the
data. One of the oddities about that disease is that the
rating scale which is used in clinical trials can also be
self-reported. Correlations between clinician interview
and patient self-report is very high – it’s above 0.9 (on
the ALSFRS-R [Amyotrophic Lateral Sclerosis Func-
tional Rating Scale–revised] scale). What that means is,
the patients have access to almost the same quality
resolution of information, of measurement, that the
doctors did.
So they started using Google Spreadsheets to exchange
their experiences with lithium, to compare their func-
tional rating scores, dosage and side effects. They started
running statistical tests on their data. In particular,
Karen had a PhD in geology, which is not a medical
science, but it’s still a science. She was running t-tests to
compare the outcomes in people who were self-reporting
that they were taking lithium vs. a control sample who
were not.
I think this raises a number of interesting questions,
but one thing that I think can’t be overlooked is that the
Figure 1 Conceptual overview of the online study environment and matching algorithm. (a) The number of patients choosing to
experiment with lithium carbonate peaked in the months after publication of a small clinical trial in Italy. Preliminary negative results from this
patient-led study were announced before the first randomized control trial had started recruitment. (b) Aggregate view of FRS scores for all 348
patients analyzed in this study. These data were publicly available online during the study. (c) Illustration of disease progression curves of control
individuals who are good and poor matches for a particular patient. Both control individuals would be considered comparable by traditional
matching criteria. The PatientsLikeMe matching algorithm minimizes the area between the disease progression curves for a target patient and a
control. Adapted from [6] with permissions.
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of the right questions. They were analyzing the original
study that had been published in PNAS and saying, “I’m
not sure about the confidence intervals on this graph,” or,
“What was the dosage here?” or “Is this the right statistical
test that they used? And was this single-blinded or double-
blinded?” They were picking the study apart just like a
peer reviewer would. I think we often don’t give partici-
pants and patients enough credit for being able to do that.
In the end, what happened was that we upgraded our
platform on PatientsLikeMe, to allow people to more
systematically measure these things so we could break out
not just the total score but also the component items; we
could more rigorously capture longitudinal data over time;
and we could capture data in a way that was probably a
bit more robust than Google Spreadsheets. We had a
dialogue open with the community the whole time about
where we were with the analysis, and people gave us sug-
gestions. When it came time to publish the paper, we pub-
lished it in an open access journal so that all the members
of the community could read it. Another thing that we did
was we actually uploaded the entire de-identified dataset
to the community, so that other people wanted to take
that data and re-analyze it, they could.
4. Are there any risks to this type of research?
Historically, there have been signs of people perhaps
rebelling against the system. In some cases, people with
HIV in clinical trials would register at multiple clinics to
try to make sure they were getting the treatment, not
the placebo. Sometimes they would even meet up in per-
son and swap pills; they would have “pill parties” so that
people would get equal chances of placebo and treatment.The medical establishment thinks that the purpose of a
trial is to learn something, but I think that these behaviors
were an early indication that many patients think that the
purpose of a trial is to get better. When these two things
come into conflict, there’s some tension there.
What the Internet and some of the tools that technol-
ogy has allowed is for the patients to actually become
more on parity with the medical establishment. If they
have access to some of the same tools — e.g. online
courses, Wikipedia, open access publications – then I
think we have to react to that. Otherwise, there are some
risks that if we don’t react and we don’t build construct-
ive ways in which we can harness this energy, it’ll actu-
ally backfire – it’ll actually be counterproductive – for
both patients and the research field.
5. How will current ethical guidelines for research need to
adapt to participant-led research?
I think, relative to our understanding of ethics as they
exist in the developed world, in response to the Declar-
ation of Helsinki, the Nuremberg trials and the Belmont
report, participant-led research turns that on its head.
Those reports and those ethical rules assume that there
is such a thing as a researcher and such a thing as a par-
ticipant, and that there’s never a situation in which one
person can be both things. I think it assumes an imbal-
ance of power where one person knows more than the
other, has access to more social capital and somehow
controls the other person. I think there’s a lot of stuff in
there around protection of prisoners, of vulnerable people,
that sort of thing. It doesn’t really take into account what
can happen when the people themselves who have a con-
dition want to self-experiment. I think we really need to
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ent here.
I don’t think there are any easy answers, but for instance
in the lithium study, one of the main people who was
proposing the patients do it was a patient living in
Brazil, using Google Translate to communicate with
English-speaking people around the world. Which IRB
[institutional review board], which ethics committee is
responsible for that? Lithium carbonate, at the time,
was generic. It was made by dozens of manufacturers
and it cost pennies. Is there a manufacturer that should
take responsibility for that? Was the responsibility for
each individual patient down to the doctor who wrote
the prescription, because they were off-label prescrip-
tions? Does some responsibility lie with PatientsLikeMe
as a place that collected the data and published the
research? I think that’s all unclear. But I think until the
research establishment has more of a discussion about
this, we’re not really sure where to go.
I think what you can’t do is close it all down; you can’t
put the genie back in the bottle. Because if it weren’t
PatientsLikeMe, it would be Google, or it would be Twit-
ter, or it would be Facebook. You can run participant-led
research over the telephone. The medium is not the issue
here. The issue is this social activation that’s occurred and
the really simple group formation that social media allows.
Unfortunately, sometimes these things get tested when
things go wrong. So we’ve been very carefully keeping an
eye on other experiments that are going on in our
platform and in the world more generally.
6. So, if patients start to take more control of the
direction of research into their disease, how might this
affect the patient-physician relationship?
In terms of the relationship with the clinician, I think
it really varies with the condition to some extent. If
you have quite a specialist condition like a neurological
disease or a cancer, for example, frequently you’ll be
dealing with a clinician who’s often involved in research.
So I think they will take a keen interest in participant-led
research, and my hope is that through clinician interfaces
to these patient platforms – whether it’s PatientsLikeMe
or somewhere else – the clinician will use that tool to
keep an eye on their own patients.
The other very important space we have to think about is
where clinicians aren’t involved in research. For instance, if
you, as a relatively healthy person, are dealing with some-
thing like insomnia, diabetes, your weight, etc. – you prob-
ably are already self-experimenting. You cut out caffeine,
you take up running – you do whatever it is that you have
to do. So, there is some degree of self-experimentation
already going on. I think the question is: at what threshold
do we need to start informing people about what we’re
doing, what we’re experimenting with?Certainly, if you’re using a drug, that crosses a clear
threshold. But what about dietary changes, what about
supplements, what about some levels of exercise? I think
there’s probably a point at which we need to either en-
courage patients to tell their clinicians or encourage cli-
nicians to ask their patients: “What else are you trying?”
We certainly know in cancer and other neurological
diseases that a fairly substantial minority of patients –
around 15 to 20% – are taking off-label or complemen-
tary and alternative medicines and not telling their doc-
tors. In the case where that’s a multivitamin, that’s one
thing. But it’s a more serious issue if the patient is taking
St. John’s wort or something that’s psychoactive or that
could potentially have an interaction with a prescribed
drug.
It’s somewhat dependent on the condition, but we also
have to be mindful of the clinician’s attitudes to this. I
think there are some things they could say that could
potentially damage that patient–physician relationship.
And this may not be for everybody; I would predict that
some clinicians will naturally attract patients who are
willing to self-experiment, and other clinicians will say,
“No, I need to be able to control the parameters, control
the variables, because I am ultimately responsible for
your health and, if you are going to self-experiment, then
I’m not sure we’re going to be able to work together on
this.” That’s a different model. That’s saying that we’re
tackling this condition together.
I think most doctors who are forward-looking and
progressive would think of the problem that way. Cer-
tainly, people who work in terminal illnesses have been
familiar with this for quite a while.
7. Are there any other challenges or limitations this form
of research? For example, levels of bias?
In terms of the challenges that we have to face, I think
there are a few things that are common to all research
projects. One is bias. Certainly, when we’ve compared the
PatientsLikeMe sample, for instance in multiple sclerosis,
with a tertiary research centre in Boston that sees thou-
sands of patients, we found the group of people who self-
report and join PatientsLikeMe tend to be younger, are
more likely to be female, and tend to be slightly better ed-
ucated. But the important point is – not to the extent that
you might think (see Figure 2). They are a couple of years
younger. They’re a few percentage points more likely to be
female. This is not such a big bias that you can’t override
it either by stratified sampling or by sample weighting. So
these factors are addressable.
The other question is – compared with what? We’ve
looked at data in organ transplants, for instance, where in
the United States every organ transplant patient is catalo-
gued, barcoded, and followed up in rigorous detail. Most
diseases don’t have this level of detail recorded. So when
Figure 2 Comparison of the individual and disease characteristics of the PatientsLikeMe.com members with those of patients followed
at the Partners MS Center. Adapted from [16] with permissions.
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gia is biased, well, we’ve got data points from 43,000 mem-
bers in our system (last updated on June 2014). There are
no other databases that large – so how would I know? If
I’m biased relative to the consecutive case series of 120
patients in the literature – how do I know that they’re not
biased? It’s very hard to tell. So that’s one of the issues that
we have to solve.
The next issue is around a classic problem: on the
Internet, no one knows you’re a dog. Well, on the Internet,
how can anyone be sure that you’re a patient? You might
have multiple sclerosis; you might think you have multiple
sclerosis; you might not have multiple sclerosis but you’re
trying to influence the community for some nefariouspurpose or just because you’re messing around. Who
knows? I think the degree to which we need to solve that
depends on what problem we’re trying to solve.
If we’re going for a very rigorous high-end question
like – should a regulator or a payer decide whether or
not this drug is worth approving? – I think the data on
which that is based have to be from people who’ve given
some other level of verification that they are who they
say they are. That could be as high as their doctor has
signed a form, or it might not have to get quite that ex-
treme. I think as people’s access to their medical records
gets simpler, you could imagine them giving permission
to other systems to use that data. In the same way that
you have permissions around what the government can
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or transfer to other banks under agreements like Direct
Debit, for instance, you could imagine being able to
determine the circumstances under which your personal
information can be shared with other organizations–
whether that’s universities or industry. That would allow
us to upgrade the quality of the data, but still allow
users and participants to retain a level of control.
The third issue is just familiarity. The people who
make decisions about diseases, treatments, or health
systems need to get more comfortable and more familiar
with this sort of data. That’s why I think it’s very import-
ant to publish in the peer reviewed literature and to
publish in open access journals where possible, so that
there aren’t barriers to people reading these studies. It’s
important to try out different data sources. Real-world
data sources are messy data-wise – it’s certainly not as
clean as a clinical trial, but it may be more generalizable.
I think that’s another place where there is both a limita-
tion but a potential strength: data taken through online sys-
tems, or digital systems, may or may not be generalizable,
depending on the condition. Those biases that I mentioned
earlier don’t do very well if what you’re ultimately trying to
study is, for example, schizophrenia in people who are
homeless. You’re going to struggle to do that. But if your
research question is around working-age women with
multiple sclerosis, well, those demographics of younger
and female actually work to your advantage. So I think it’s
a question of actually picking out those populations where
the bias and generalizability can be addressed, and looking
at the status quo – where the databases and the samples
are quite small.
8. Recently, Open Research Exchange (ORE) was created
to facilitate collaboration between clinical researchers,
academics, and patients. How does ORE expect to
improve health outcome measurements?
A big part of building a learning healthcare system is
about building the correct measurements. We can only
look after our weight because we have weighing scales
and there are labels in our clothes that tell us how big
we are. For most of the thousands of medical conditions
that exist, there are no such measures. You can’t line up
a row of people from end to end and say “this is the per-
son with the worst autism or OCD for instance, and this
is the person with the least worst” in such a way that is
anywhere near as scientifically and psychometrically as
rigorous as we can with blood pressure or weight or
height, or anything that’s more measurable.
This can be addressed to some extent. There are patient-
reported outcome (PRO) measures, where through just
questions and surveys, patients can tell us about their ex-
perience of a disease. That’s particularly important about
things like pain, about symptoms, about quality of life, orabout the impact of disease on the activities of daily living.
Perhaps we can have an objective measure in something
like rheumatoid arthritis from a blood test, but what we’re
really interested in is: “how well can you open a jar?” or
“how well can you function in the real world?” PROs really
allow you to do that.
The issue, however, is that there aren’t many PROs.
There’s the PROQOLID [Patient-Reported Outcome and
Quality of Life Instruments Database ] that estimates
there’s a little under 1,000 PROs, and if there’s about
7,000 diseases in ICD [International Classification of
Diseases] and about 7,000 rare diseases that don’t even
have names, then we need more measurements. The
other issue is that many of these measurements were
developed a long time ago, so they suffer from anachro-
nisms; they say, “how full of pep are you?”; they ask, in
an Asperger’s screening instrument, whether or not you
can program a VCR [video cassette recorder]. In this
world of TiVos and DVRs [digital video recorders], that’s
no longer relevant.
What we need is a way of developing PROs faster. We
could also do with reducing limitations on them. Many
of the PROs are licensed, copyrighted instruments – you
have to pay thousands of dollars for a license fee or sev-
eral dollars per use, and that limits their use. It restricts
their use in innovation and in app development, and
restricts them only to expensive and well-funded clinical
trials.
The point of the Open Research Exchange – funded
by a grant from the Robert Wood Johnson Foundation –
is to overlay a platform on top of PatientsLikeMe, which
allows researchers to come and enter their prototype
PRO measures, and for patients on our system to come
and help to improve them. So, for instance, if there’s a
question like, “How frequently do you experience suicidal
ideation?” we can target a patient who we know has had
a mood disorder in the past to come and provide feed-
back on that question. They might say something like,
“Well, gosh, I don’t know what ideation means. Do you
mean have I had thoughts about killing myself? That’s a
question that I can relate to.” We can get more patients
to look at that quickly, have the researcher iterate on
that question, and then get another group of patients to
come and provide further feedback. So we can very
quickly improve upon individual questions.
You could also field it to a larger sample – to a few
hundred people who are willing to be volunteers so that
psychometric information can be gathered rapidly. So
through item response theory we could ask, do we see
enough segregation between the people saying “not at
all” and “a little bit” or “somewhat”? Are these the right
categories or should we use a 1 to 7 scale, or a 1 to 5
scale? There are psychometric statistical answers to that,
but we frequently don’t get them in medicine because
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one version with five items and one version with seven
items. However, because these people are online, they
have the time to do that and they’re willing to do that.
In 2013, the mission was to develop three PRO mea-
sures rapidly and so far we’re on track to achieve that
in a number of different areas. All those instruments
will be licensed under a Creative Commons Sharealike
licence, which means that they can be built upon and
translated, and what we’re trying to build is an ecosys-
tem around which PRO developers can come in and
volunteer to help out other people. So, if you have a
statistical skill and a little bit of spare time, or if you’re a
good item developer, you could help your peers. We
could create item banks and libraries of instruments so
that if someone comes in, for example a parent who’s
very well motivated and wants to develop a PRO for
their child with a developmental disorder that has some
characteristics of autism and Down’s syndrome, for
instance, we could take those items that have tested well
and build that into a new scale. Because it’s all under
Creative Commons, we can reuse that work without
having to worry so much about that copyright, and then
go on to build new instruments.
So, it’s sort of an open library. Our software engineers
talk about it as GitHub for PROs, which is a software
development tool that allows a lot of open access work.
Next year [in 2014], what we’ll be looking at is trying to
bring in more of those patients, more of those care-
givers. When you let the software take off some of the
heavy lifting, you’re able to concentrate on what you ac-
tually want to do. In this case, that would be: share your
experience of what it’s like to live with a disease and give
feedback to the researchers on what it’s actually like to
be a patient.
9. How do you expect this field to develop in the next
few years?
My hope is that people will be open to some of these
ideas because, who knows, one of our participant-led
research projects could be right. It could be successful. I
think much of the existing scientific endeavor is set up
around new, patentable pharmaceutical molecules. But
in the case where it’s exercise or diet or something like
that – maybe even a behavioral modification – there’s
not a large well-funded machine behind it that can go
and study that, which means that we can miss out. There
are many conditions – diabetes is a perfect example –
where those things can be just as effective, if not more so,
without the side effects. But unless we build a system that
captures that and allows it to filter back into the medical
system, it’s going to remain just a sideshow on the out-
skirts. The next few years, I’m really expecting the govern-
ments of the world to wake up to this, for the healthsystems of the world to wake up to this, and to start
engaging a bit more with the problem.
I think a lot of the participant-led research world has
come from patients and participants, as you would
expect. Frequently, people who are professionals in their
working lives then get sick and have come from a very
high-tech environment like architecture or engineering
or town planning, and then they get ill and they’re
amazed that these systems don’t exist and so they go
and build them. That’s fantastic, that’s great, it means
they come from exactly the right place. But at some
point, these things need to scale up. They need to start
interacting with the health system, and the health system
is controlled by a variety of large players and big barriers
to entry, and they are sometimes a little bit reticent to
innovate.
I think the opportunity here is to say – well some of
this work has been done. Some of the early barriers have
been overcome by the pioneers, the patients out there in
the field. I think now is the time for the people who run
hospitals or run decision-making bodies, to say – well
OK, what are some of the tendrils we can extend to see
if we can link up here? Not to say – is it good enough
yet? Pass or fail. But to say – well if these people did a, b
and c, then we would be able to use their data, then we
would be able to help involve them in the decisions
more. Then we’d really be able to build their system into
ours and make use of that.
Certainly, people with rare diseases have got a jump
on this because the patients are so well motivated. But
also, there are so few researchers involved in this that
really they’re interested in all the help they can get.
People like the Alkaptonuria Society (AKU), have been
extremely involved in building clinical databases of pa-
tients all over the world, centralized out from the UK.
They’re helping to run trials. They’ve even crowd-funded
the recent replication of a trial; when their funding
gap of $100,000 showed up, they didn’t just shut the
trial down, they went out on IndieGoGo and started
fundraising through their researchers, through their
communities, through their hospitals, in the same way
as some of Kickstarter commercial projects.
There are some interesting new ways that this can be
harnessed and built into the existing research infrastruc-
ture. One of the most pioneering groups in this field is
the Multiple Myeloma Research Foundation over in the
States, who’ve actually worked very closely with the
pharmaceutical industry, and even funded pharmaceut-
ical companies to develop drugs. Now, that is exactly the
opposite way round of how we normally think of a non-
profit organization or a charity. But they’ve taken a very
aggressive approach in wanting to look at treatments that
have potential and to say – well even if there’s not an
addressable market for this, we would like to make that
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pharmaceutical industry’s existing infrastructure to do the
science, to do the trials and to run those. I think we’ll see
a little bit more of that; the existing infrastructure bringing
in what’s being done out there, and sometimes even inver-
sions of how we normally think of the paradigm. So I
think those are two big trends we see.
The one trend I would love to see more of is where we
see innovation in the developing world come through into
the developed world. There’s a term “reverse innovation”,
which I’m a bit ambivalent about. But the idea there is that
you look at interventions that are cheap, that can be open
sourced. There’s a great project called Fittle, run by an eye
doctor in India who is 3D-printing toys with Braille. So
you have something like a plastic fish, it’s shaped like a fish
and it’s in four components and it’s got the Braille for F, I,
S, H. He’s open sourcing it so that anyone can print it any-
where. This is a development that if a company came up
with it, it would be very expensive, very complicated and
would have to be ordered from a catalogue, etc. But this
philosophy is saying – no, if you’ve got a 3D printer, it’s
just intellectual property, you can just make it appear and
it just costs pennies for the plastic mould. This sort of
stuff is happening with prosthetics. It’s happening with
assisted devices. It’s becoming easier and easier to do this.
That’s a really important trend we have to look at.
Innovation is not just spending millions of dollars on
big expensive technogadgets that go ‘ping’. Sometimes,
it’s getting cheap little bits of plastic and wire, and rop-
ing them together with a bit of know-how, and then dis-
tributing and assimilating that knowledge in a way that’s
low-tech, survivable, robust, and cheap, so that more
and more people can have access to and use.
10. Where can I find out more?
See references [1-21].
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